Monoclonals to SARS-CoV-2

Meridian’s antibodies are highly sensitive for the detection of SARS-CoV-2 and they are ideal for developing reliable and sensitive rapid antigen assays for the detection of active COVID-19 infections. Meridian has a novel antibody pair to trimeric SARS-CoV-2 S1 protein that is capable of recognizing the spike 1 (S1) protein in saliva samples regardless of its confirmation state (e.g. “up” or “down”). The antibodies bind to a linear epitope on the S1 protein that is distinct from the RBD protein which has epitopes that are conformation-dependent. Recent studies have shown that linear epitopes on the S1 protein are able to elicit neutralizing antibodies in COVID-19 patients and have potent antigenicity, making them prime targets for diagnostic, therapeutic, and vaccine targets. Li, Y., Lai, D., Zhang, H. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol (2020).

Catalogs & Brochures

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

About Life Science
Welcome to
logo blue

Please select your country to continue